Summary of SenesTech Q3 2025 Earnings Call

1Key Financial Results and Metrics

Total Revenue: $690,000, a 43% increase year-over-year and a 10% increase sequentially.

Evolve Product Revenue: Increased by 77%, accounting for 85% of total sales.

ContraPest Revenue: Decreased by 31%, representing 15% of sales but remained flat compared to Q2.

Gross Margin: Steady at 63%, with gross profit rising to $433,000 from $315,000.

Operating Expenses: Decreased by 4% year-over-year and 12% sequentially, aided by the removal of $100,000 in one-time legal expenses.

Adjusted EBITDA Loss: Improved to $1.2 million, the best in company history, compared to $1.4 million in the previous year.

2Strategic Updates and Business Highlights

E-commerce Growth: E-commerce sales represented 54% of total revenue, with a 55% year-over-year increase. Significant growth was noted from Amazon and new partnerships, including a launch on Lowe's e-commerce platform.

Retail Expansion: Brick-and-mortar sales surged by 254% year-over-year, driven by partnerships with ACE Hardware and Bradley Caldwell.

Municipal Market Adoption: Revenue from municipal deployments grew by 139%, with successful initiatives in cities like New York and Chicago.

Production Capacity: Transition to a new facility in Phoenix aims to enhance production efficiency and meet future demand.

3Forward Guidance and Outlook

Management expressed confidence in achieving profitability without the need for further equity offerings, supported by a cash position of over $10 million.

Continued focus on high-margin revenue growth and operational efficiency is expected to drive future performance.

Anticipation of further expansion into brick-and-mortar retail and international markets, particularly following recent approvals in New Zealand.

4Bad News, Challenges, or Points of Concern

Legal Challenges: The company is facing a lawsuit from Liphatech regarding alleged IP infringement, which could lead to additional legal expenses and distract from business operations.

ContraPest Performance: The decline in ContraPest sales raises concerns about reliance on Evolve for future revenue growth.

International Market Delays: While progress is being made, approvals in international markets are taking longer than expected, potentially delaying revenue from these areas.

5Notable Q&A Insights

Lowe's Brick-and-Mortar Plans: Discussions are ongoing for potential test deployments in about 100 Lowe's stores by the end of Q2 2026.

PMP Sales Growth: Pest Management Professionals (PMPs) accounted for 19% of sales, with expectations for significant growth as awareness of Evolve as a pest control solution increases.

Pricing Strategy: The company is comfortable with its current pricing strategy for Evolve but is open to adjustments to secure larger orders if necessary.

International Market Progress: New Zealand has granted approval for Evolve, and the company is optimistic about securing additional international approvals in the coming months. Overall, SenesTech reported a strong quarter with significant revenue growth and operational improvements, while also facing challenges related to legal issues and product performance. The company remains focused on strategic expansion and profitability.